Seizure: European Journal of Epilepsy
Volume 19, Issue 6 , Pages 311-318 , July 2010

Is elevated norepinephrine an etiological factor in some cases of epilepsy?

  • Paul J. Fitzgerald

      Affiliations

    • Corresponding Author InformationCurrent address: National Institute on Alcohol Abuse and Alcoholism (NIAAA), 5625 Fishers Lane, Room 2N09, Bethesda, MD 20852-9411, USA. Tel.: +1 443 564 1306.

Received 18 August 2009 ,Revised 1 April 2010 ,Accepted 23 April 2010.

References 

  1. Giorgi FS, Pizzanelli C, Biagioni F, Murri L, Fornai F. The role of norepinephrine in epilepsy: from the bench to the bedside. Neurosci Biobehav Rev. 2004;28:507–524
  2. Dailey JW, Jobe PC. Anticonvulsant drugs and the genetically epilepsy-prone rat. Fed Proc. 1985;44:2640–2644
  3. Szot P, Weinshenker D, White SS, Robbins CA, Rust NC, Schwartzkroin PA, et al. Norepinephrine-deficient mice have increased susceptibility to seizure-inducing stimuli. J Neurosci. 1999;19:10985–10992
  4. Weinshenker D, Szot P, Miller NS, Palmiter RD. Alpha(1) and beta(2) adrenoreceptor agonists inhibit pentylenetetrazole-induced seizures in mice lacking norepinephrine. J Pharmacol Exp Ther. 2001;298:1042–1048
  5. Szot P, Lester M, Laughlin ML, Palmiter RD, Liles LC, Weinshenker D. The anticonvulsant and proconvulsant effects of alpha2-adrenoreceptor agonists are mediated by distinct populations of alpha2A-adrenoreceptors. Neuroscience. 2004;126:795–803
  6. Martillotti J, Weinshenker D, Liles LC, Eagles DA. A ketogenic diet and knockout of the norepinephrine transporter both reduce seizure severity in mice. Epilepsy Res. 2006;68:207–211
  7. Nylen K, Likhodii S, Burnham WM. The ketogenic diet: proposed mechanisms of action. Neurotherapeutics. 2009;6:402–405
  8. Kaminski RM, Shippenberg TS, Witkin JM, Rocha BA. Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures. Neurosci Lett. 2005;382:51–55
  9. Ahern TH, Javors MA, Eagles DA, Martillotti J, Mitchell HA, Liles LC, et al. The effects of chronic norepinephrine transporter inactivation on seizure susceptibility in mice. Neuropsychopharmacology. 2006;31:730–738
  10. Jobe PC, Browning RA. The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav. 2005;7:602–619
  11. Dailey JW, Naritoku DK. Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem Pharmacol. 1996;52:1323–1329
  12. Gibson AP, Bettinger TL, Patel NC, Crismon ML. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother. 2006;40:1134–1142
  13. Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1106–1117
  14. Post RM. Time course of clinical effects of carbamazepine: implications for mechanisms of action. J Clin Psychiatry. 1988;49(Suppl.):35–48
  15. Meyer JS, Quenzer LF. Psychopharmacology: drugs, the brain, and behavior. 136. Sunderland, MA: Sinauer Associates, Inc.; 2005;397
  16. Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004;59:5–12
  17. Jordan S, Kramer GL, Zukas PK, Moeller M, Petty F. In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse. 1994;18:294–297
  18. Krijzer F, Snelder M, Bradford D. Comparison of the (pro)convulsive properties of fluvoxamine and clovoxamine with eight other antidepressants in an animal model. Neuropsychobiology. 1984;12:249–254
  19. Peterson SL, Trzeciakowski JP, St Mary JS. Chronic but not acute treatment with antidepressants enhances the electroconvulsive seizure response in rats. Neuropharmacology. 1985;24:941–946
  20. Warter JM, Tranchant C, Marescaux C, Depaulis A, Lannes B, Vergnes M. Immediate effects of 14 non MAOI antidepressants in rats with spontaneous petit mal-like seizures. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:261–270
  21. Ago J, Ishikawa T, Matsumoto N, Ashequr Rahman M, Kamei C. Mechanism of imipramine-induced seizures in amygdala-kindled rats. Epilepsy Res. 2006;72:1–9
  22. Clifford DB, Rutherford JL, Hicks FG, Zorumski CF. Acute effects of antidepressants on hippocampal seizures. Ann Neurol. 1985;18:692–697
  23. Yacobi R, Burnham WM. The effect of tricyclic antidepressants on cortex- and amygdala-kindled seizures in the rat. Can J Neurol Sci. 1991;18:132–136
  24. Lancaster JM, Davies JA. Desmethylimipramine potentiates NMDA responses in a mouse cortical slice preparation. Neuroreport. 1991;2:665–668
  25. Arai S, Morita K, Kitayama S, Kumagai K, Kumagai M, Kihira K, et al. Chronic inhibition of the norepinephrine transporter in the brain participates in seizure sensitization to cocaine and local anesthetics. Brain Res. 2003;964:83–90
  26. Kleinrok Z, Gustaw J, Czuczwar SJ. Influence of antidepressant drugs on seizure susceptibility and the anticonvulsant activity of valproate in mice. J Neural Transm Suppl. 1991;34:85–90
  27. Sun XY, Zhang L, Wei CX, Piao HR, Quan ZS. Characterization of the anticonvulsant activity of doxepin in various experimental seizure models in mice. Pharmacol Rep. 2009;61:245–251
  28. Koella WP, Glatt A, Klebs K, Durst T. Epileptic phenomena induced in the cat by the antidepressants maprotiline, imipramine, clomipramine, and amitriptyline. Biol Psychiatry. 1979;14:485–497
  29. Pineda MR, Russell SC. The use of a tricyclic antidepressant in epilepsy. Dis Nerv Syst. 1974;35:322–323
  30. Petti TA, Campbell M. Imipramine and seizures. Am J Psychiatry. 1975;132:538–540
  31. Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry. 1992;53:160–162
  32. Eyer F, Stenzel J, Schuster T, Felgenhauer N, Pfab R, von Bary C, et al. Risk assessment of severe tricyclic antidepressant overdose. Hum Exp Toxicol. 2009;28:511–519
  33. Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry. 1983;44:197–201
  34. Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract. 2005;59:1435–1440
  35. Kuhn KU, Quednow BB, Thiel M, Falkai P, Maier W, Elger CE. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy Behav. 2003;4:674–679
  36. Wernicke JF, Holdridge KC, Jin L, Edison T, Zhang S, Bangs ME, et al. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol. 2007;49:498–502
  37. McAfee AT, Holdridge KC, Johannes CB, Hornbuckle K, Walker AM. The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database. Curr Drug Saf. 2008;3:123–131
  38. Kashani J, Ruha AM. Isolated atomoxetine overdose resulting in seizure. J Emerg Med. 2007;32:175–178
  39. Golan DE, Tashjian AH, Armstrong EJ, Galanter JM, Armstrong AW, Arnaout RA, et al. Principles of pharmacology: the pathophysiologic basis of drug therapy;. Baltimore, MD: Lippincott Williams & Wilkins; 2005;p. 110
  40. Tacke U, Kolonen S. The effect of clonidine and yohimbine on audiogenic seizures (AGS) in rats. Pharmacol Res Commun. 1984;16:1019–1030
  41. Kleinlogel H. Spontaneous EEG paroxysms in the rat: effects of psychotropic and alpha-adrenergic agents. Neuropsychobiology. 1985;13:206–213
  42. Wu HQ, Tullii M, Samanin R, Vezzani A. Norepinephrine modulates seizures induced by quinolinic acid in rats: selective and distinct roles of alpha-adrenoceptor subtypes. Eur J Pharmacol. 1987;138:309–318
  43. Ashton D, Wauquier A. Alpha-noradrenaline modulation of d,l-allylgycine seizures. Eur J Pharmacol. 1981;75:71–74
  44. Papanicolaou J, Summers RJ, Vajda FJ, Louis WJ. The relationship between alpha 2-adrenoceptor selectivity and anticonvulsant effect in a series of clonidine-like drugs. Brain Res. 1982;241:393–397
  45. Lazarova M, Bendotti C, Samanin R. The role of different types of adrenergic receptors in pentylenetetrazol-induced seizures and the effect of di-n-propylacetate in the rat. Psychopharmacology. 1983;81:177–182
  46. Mueller AL, Dunwiddie TV. Anticonvulsant and proconvulsant actions of alpha- and beta-noradrenergic agonists on epileptiform activity in rat hippocampus in vitro. Epilepsia. 1983;24:57–64
  47. Baran H, Hortnagl H, Hornykiewicz O. Kainic acid-induced seizures: potentiation by alpha-methyl-p-tyrosine. Brain Res. 1989;495:253–260
  48. Chermat R, Doare L, Lachapelle F, Simon P. Effects of drugs affecting the noradrenergic system on convulsions in the quaking mouse. Naunyn Schmiedebergs Arch Pharmacol. 1981;318:94–99
  49. Horton R, Anlezark G, Meldrum B. Noradrenergic influences on sound-induced seizures. J Pharmacol Exp Ther. 1980;214:437–442
  50. Homeida AM, Cooke RG. Anti-convulsant activity of diazepam and clonidine on metaldehyde-induced seizures in mice: effects on brain gamma-amino butyric acid concentrations and monoamine oxidase activity. J Vet Pharmacol Ther. 1982;5:187–190
  51. Amabeoku GJ. The involvement of noradrenaline, 5-hydroxytryptamine and acetylcholine in imipramine-induced seizures in mice. Experientia. 1993;49:859–864
  52. Amabeoku G, Chandomba R. Strychnine-induced seizures in mice: the role of noradrenaline. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:753–763
  53. Kirchberger K, Schmitt H, Hummel C, Peinemann A, Pauli E, Kettenmann B, et al. Clonidine and methohexital-induced epileptic magnetoencephalographic discharges in patients with focal epilepsies. Epilepsia. 1998;39:841–849
  54. Kettenmann B, Feichtinger M, Tilz C, Kaltenhauser M, Hummel C, Stefan H. Comparison of clonidine to sleep deprivation in the potential to induce spike or sharp-wave activity. Clin Neurophysiol. 2005;116:905–912
  55. Neuman RS. Suppression of penicillin-induced focal epileptiform activity by locus ceruleus stimulation: mediation by an alpha 1-adrenoceptor. Epilepsia. 1986;27:359–366
  56. Jackson HC, Dickinson SL, Nutt DJ. Exploring the pharmacology of the pro-convulsant effects of alpha 2-adrenoceptor antagonists in mice. Psychopharmacology. 1991;105:558–562
  57. Loscher W, Czuczwar SJ. Comparison of drugs with different selectivity for central alpha 1-and alpha 2-adrenoceptors in animal models of epilepsy. Epilepsy Res. 1987;1:165–172
  58. Nicoletti F, Barbaccia ML, Iadarola MJ, Pozzi O, Laird HE. Abnormality of alpha 1-adrenergic receptors in the frontal cortex of epileptic rats. J Neurochem. 1986;46:270–273
  59. Jazrawi SP, Horton RW. Brain adrenoceptor binding sites in mice susceptible(DBA/2J) and resistant (C57 Bl/6) to audiogenic seizures. J Neurochem. 1986;47:173–177
  60. Kunieda T, Zuscik MJ, Boongird A, Perez DM, Luders HO, Najm IM. Systemic overexpression of the alpha 1B-adrenergic receptor in mice: an animal model of epilepsy. Epilepsia. 2002;43:1324–1329
  61. Pizzanelli C, Lazzeri G, Fulceri F, Giorgi FS, Pasquali L, Cifelli G, et al. Lack of alpha 1b-adrenergic receptor protects against epileptic seizures. Epilepsia. 2009;50(Suppl 1):59–64
  62. Briere R, Sherwin AL, Robitaille Y, Olivier A, Quesney LF, Reader TA. Alpha-1 adrenoceptors are decreased in human epileptic foci. Ann Neurol. 1986;19:26–30
  63. Ferraro G, Sardo P, Sabatino M, Caravaglios G, La Grutta V. Anticonvulsant activity of the noradrenergic locus coeruleus system: role of beta mediation. Neurosci Lett. 1994;169:93–96
  64. Louis WJ, Papanicolaou J, Summers RJ, Vajda FJ. Role of central beta-adrenoceptors in the control of pentylenetetrazol-induced convulsions in rats. Br J Pharmacol. 1982;75:441–446
  65. Paul V, Krishnamoorthy MS. The effect of beta-adrenoceptor antagonists alone and in combination with a GABA-elevating agent on isoniazid-induced convulsions in rats. Indian J Physiol Pharmacol. 1989;33:175–178
  66. Nakamura T, Oda Y, Takahashi R, Tanaka K, Hase I, Asada A. Propranolol increases the threshold for lidocaine-induced convulsions in awake rats: a direct effect on the brain. Anesth Analg. 2008;106:1450–1455
  67. Gross RA, Ferrendelli JA. Relationships between norepinephrine and cyclic nucleotides in brain and seizure activity. Neuropharmacology. 1982;21:655–661
  68. Wambebe C, Osuide G, Gamaniel K. Influence of levodopa, apomorphine and 3,4-dihydroxyphenylserine (DOPS) on strychnine-induced seizures in mice. Gen Pharmacol. 1984;15:243–245
  69. Lints CE, Nyquist-Battie C. A possible role for beta-adrenergic receptors in the expression of audiogenic seizures. Pharmacol Biochem Behav. 1985;22:711–716
  70. Khanna N, Ray A, Alkondon M, Sen P. Effect of beta-adrenoceptor antagonists and some related drugs on maximal electroshock seizures in mice. Indian J Exp Biol. 1989;27:128–130
  71. Raju SS, Gopalakrishna HN, Venkatadri N. Effect of propranolol and nifedipine on maximal electroshock-induced seizures in mice: individually and in combination. Pharmacol Res. 1998;38:449–452
  72. De Sarro G, Di Paola ED, Ferreri G, De Sarro A, Fischer W. Influence of some beta-adrenoceptor antagonists on the anticonvulsant potency of antiepileptic drugs against audiogenic seizures in DBA/2 mice. Eur J Pharmacol. 2002;442:205–213
  73. Fischer W. Anticonvulsant profile and mechanism of action of propranolol and its two enantiomers. Seizure. 2002;11:285–302
  74. Fowler GW. Propanolol treatment of infantile polymyoclonia. Neuropadiatrie. 1976;7:443–449
  75. de Oliveira GG, Borges MA. Propranolol action in chronically unstable generalized epilepsy. Am J Ther. 1994;1:38–41
  76. Levitt P, Noebels JL. Mutant mouse tottering: selective increase of locus ceruleus axons in a defined single-locus mutation. Proc Natl Acad Sci USA. 1981;78:4630–4634
  77. Levitt P. Normal pharmacological and morphometric parameters in the noradrenergic hyperinnervated mutant mouse, “tottering”. Cell Tissue Res. 1988;252:175–180
  78. Noebels JL. A single gene error of noradrenergic axon growth synchronizes central neurones. Nature. 1984;310:409–411
  79. Hardebo JE, Owman C. Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood–brain interface. Ann Neurol. 1980;8:1–31
  80. Devinsky O, Price BH, Cohen SI. Cardiac manifestations of complex partial seizures. Am J Med. 1986;80:195–202
  81. Stoba C, Skoczylas-Stoba B, Czauderna P. Clinical course and treatment of pheochromocytomas in children. Analysis of five cases. Eur J Pediatr Surg. 1993;3:154–156
  82. Reichardt P, Apel TW, Domula M, Trobs RB, Krause I, Bierbach U, et al. Recurrent polytopic chromaffin paragangliomas in a 9-year-old boy resulting from a novel germline mutation in the von Hippel-Lindau gene. J Pediatr Hematol Oncol. 2002;24:145–148
  83. Leiba A, Bar-Dayan Y, Leker RR, Apter S, Grossman E. Seizures as a presenting symptom of phaeochromocytoma in a young soldier. J Hum Hypertens. 2003;17:73–75
  84. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509–522
  85. Jimerson DC, Nurnberger JI, Post RM, Gershon ES, Kopin IJ. Plasma MHPG in rapid cyclers and healthy twins. Arch Gen Psychiatry. 1981;38:1287–1290
  86. Barry JJ. The recognition and management of mood disorders as a comorbidity of epilepsy. Epilepsia. 2003;44:30–40
  87. Ettinger AB, Reed ML, Goldberg JF, Hirschfeld RM. Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology. 2005;65:535–540
  88. Mula M, Schmitz B, Jauch R, Cavanna A, Cantello R, Monaco F, et al. On the prevalence of bipolar disorder in epilepsy. Epilepsy Behav. 2008;13:658–661
  89. Mula M, Jauch R, Cavanna A, Collimedaglia L, Barbagli D, Gaus V, et al. Manic/hypomanic symptoms and quality of life measures in patients with epilepsy. Seizure. 2009;18:530–532
  90. Roxanas MG, Corbett AJ, Reid WG. A patient with mania and photoconvulsive epilepsy. Aust N Z J Psychiatry. 1996;30:867–870
  91. Mula M, Marotta AE, Monaco F. Epilepsy and bipolar disorders. Expert Rev Neurother. 2010;10:13–23
  92. Salpekar JA, Conry JA, Doss W, Cushner-Weinstein S, Pearl PL, Weinstein SL, et al. Clinical experience with anticonvulsant medication in pediatric epilepsy and comorbid bipolar spectrum disorder. Epilepsy Behav. 2006;9:327–334
  93. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol. 2008;11:999–1029
  94. Solt VB, Brown MR, Kennedy B, Kolterman OG, Ziegler MG. Elevated insulin, norepinephrine, and neuropeptide Y in hypertension. Am J Hypertens. 1990;3:823–828
  95. Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007;9:399–405
  96. Eide I, Kolloch R, DeQuattro V, Miano L, Dugger R, Van der Meulen J. Raised cerebrospinal fluid norepinephrine in some patients with primary hypertension. Hypertension. 1979;1:255–260
  97. DeQuattro V, Sullivan P, Minagawa R, Kopin I, Bornheimer J, Foti A, et al. Central and peripheral noradrenergic tone in primary hypertension. Fed Proc. 1984;43:47–51
  98. Kawano Y, Fukiyama K, Takeya Y, Abe I, Omae T. Catecholamines, angiotensin II and sodium concentrations in cerebrospinal fluid in young men with borderline hypertension. Clin Exp Hypertens A. 1984;6:1131–1145
  99. Hesdorffer DC, Hauser WA, Annegers JF, Rocca WA. Severe, uncontrolled hypertension and adult-onset seizures: a case–control study in Rochester, Minnesota. Epilepsia. 1996;37:736–741
  100. Li X, Breteler MM, de Bruyne MC, Meinardi H, Hauser WA, Hofman A. Vascular determinants of epilepsy: the Rotterdam Study. Epilepsia. 1997;38:1216–1220
  101. Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML. Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation. 2005;111:3429–3434
  102. Oltmans GA, Lorden JF, Margules DL. Effects of food restriction and mutation on central catecholamine levels in genetically obese mice. Pharmacol Biochem Behav. 1976;5:617–620
  103. Oltmans GA. Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob). Brain Res. 1983;273:369–373
  104. Shimazu T, Noma M, Saito M. Chronic infusion of norepinephrine into the ventromedial hypothalamus induces obesity in rats. Brain Res. 1986;369:215–223
  105. Kobau R, DiIorio CA, Price PH, Thurman DJ, Martin LM, Ridings DL, et al. Prevalence of epilepsy and health status of adults with epilepsy in Georgia and Tennessee: Behavioral Risk Factor Surveillance System, 2002. Epilepsy Behav. 2004;5:358–366
  106. Daniels ZS, Nick TG, Liu C, Cassedy A, Glauser TA. Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy. Neurology. 2009;73:658–664
  107. Gilliam FG, Mendiratta A, Pack AM, Bazil CW. Epilepsy and common comorbidities: improving the outpatient epilepsy encounter. Epileptic Disord. 2005;7(Suppl. 1):S27–S33
  108. Wong J, Wirrell E. Physical activity in children/teens with epilepsy compared with that in their siblings without epilepsy. Epilepsia. 2006;47:631–639
  109. Homayoun H, Khavandgar S, Dehpour AR. The role of alpha2-adrenoceptors in the modulatory effects of morphine on seizure susceptibility in mice. Epilepsia. 2002;43:797–804
  110. Tabb K, Boss-Williams KA, Weiss JM, Weinshenker D. Rats bred for susceptibility to depression-like phenotypes have higher kainic acid-induced seizure mortality than their depression-resistant counterparts. Epilepsy Res. 2007;74:140–146
  111. Swinkels WA, Engelsman M, Kasteleijn-Nolst Trenite DG, Baal MG, de Haan GJ, Oosting J. Influence of an evacuation in February 1995 in The Netherlands on the seizure frequency in patients with epilepsy: a controlled study. Epilepsia. 1998;39:1203–1207
  112. Yuen AW, Thompson PJ, Flugel D, Bell GS, Sander JW. Mortality and morbidity rates are increased in people with epilepsy: is stress part of the equation?. Epilepsy Behav. 2007;10:1–7
  113. Layne Moore J, Elliot JO, Lu B, Klatte ET, Charyton C. Serious psychological distress among persons with epilepsy based on the 2005 California Health Interview Survey. Epilepsia. 2009;50:1077–1084
  114. Hiramatsu M, Fujimoto N, Mori A. Catecholamine level in cerebrospinal fluid of epileptics. Neurochem Res. 1982;7:1299–1305
  115. Laxer KD, Sourkes TL, Fang TY, Young SN, Gauthier SG, Missala K. Monoamine metabolites in the CSF of epileptic patients. Neurology. 1979;29:1157–1161
  116. Devinsky O, Emoto S, Goldstein DS, Stull R, Porter RJ, Theodore WH, et al. Cerebrospinal fluid and serum levels of dopa, catechols, and monoamine metabolites in patients with epilepsy. Epilepsia. 1992;33:263–270
  117. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26

PII: S1059-1311(10)00086-5

doi: 10.1016/j.seizure.2010.04.011

Seizure: European Journal of Epilepsy
Volume 19, Issue 6 , Pages 311-318 , July 2010

Article Tools